Kesmalea Therapeutics is developing a pipeline of small molecule protein degraders using its SELFTAC® platform, which transforms large bifunctional degraders into orally bioavailable compounds that penetrate the central nervous system. This approach addresses the limitations of traditional protein degradation therapies by enhancing drug-like properties and expanding treatment options for chronic diseases, including oncology and CNS disorders.
Funding
$24.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional bifunctional protein degraders face limitations due to their large size, resulting in poor oral bioavailability and restricted central nervous system (CNS) penetration, which hinders their effectiveness in treating chronic diseases. This size constraint limits the clinical viability and therapeutic potential of these otherwise versatile molecules.
Solution
Kesmalea Therapeutics is developing a pipeline of orally bioavailable, CNS-penetrant small molecule protein degraders using its proprietary SELFTAC® platform. This platform transforms large bifunctional degraders into smaller molecules by inserting a reversible linker, enabling self-assembly at the target location within the body. By overcoming the size limitations of traditional protein degraders, Kesmalea's approach enhances drug-like properties, improves oral bioavailability, and facilitates access to the CNS. This technology expands the range of treatable diseases, particularly in oncology and CNS disorders, by enabling effective protein degradation in previously inaccessible areas.
Target Audience
The primary target audience includes patients with chronic diseases, particularly those with oncology and CNS disorders, as well as pharmaceutical companies seeking innovative protein degradation technologies.
Features
- SELFTAC® platform technology that converts large protein degraders into orally bioavailable small molecules.
- Reversible linker technology enabling self-assembly of bifunctional degraders at the target location.
- Enhanced CNS penetration for treating neurological disorders.
- Pipeline of small molecule protein degraders in development for oncology and CNS indications.
- Potential for in-house development and collaborations with companies with complementary technologies.